Table 4 Duration of current use relative to never use of menopausal hormone therapy and risk of breast tumor characteristics

Tumor size

   ≤ 10 mm

Reference

Reference

Reference

Reference

   11 to 20 mm

1.1 (0.8 to 1.6)

1.1 (0.8 to 1.7)

1.0 (0.7 to 1.3)

1.0 (0.8 to 1.4)

   21 to 50 mm

1.4 (0.9 to 2.0)

1.2 (0.8 to 1.9)

0.6 (0.4 to 0.9)

0.6 (0.4 to 0.9)

   >50 mm

1.0 (0.4 to 2.6)

0.8 (0.3 to 2.3)

0.6 (0.2 to 1.6)

0.7 (0.2 to 1.7)

Lymph node involvement

   0 lymph nodes

Reference

Reference

Reference

Reference

   1 to 3 lymph nodes

1.0 (0.7 to 1.4)

0.8 (0.5 to 1.2)

1.2 (0.9 to 1.7)

1.1 (0.8 to 1.6)

   >3 lymph nodes

0.9 (0.6 to 1.5)

0.8 (0.5 to 1.4)

0.7 (0.4 to 1.1)

0.6 (0.4 to 1.1)

Grade

   1

Reference

Reference

Reference

Reference

   2

0.9 (0.5 to 1.6)

1.3 (0.7 to 2.4)

0.4 (0.3 to 0.7)

0.5 (0.3 to 0.7)

   3

1.3 (0.8 to 2.3)

1.5 (0.8 to 2.7)

0.3 (0.2 to 0.5)

0.3 (0.2 to 0.5)

Histology

   Ductal

Reference

Reference

Reference

Reference

   Lobular

1.4 (1.0 to 2.2)

1.5 (1.0 to 2.5)

1.9 (1.3 to 2.8)

2.0 (1.4 to 2.9)

   Other

0.8 (0.5 to 1.2)

0.9 (0.5 to 1.4)

2.0 (1.4 to 2.7)

2.0 (1.4 to 2.8)

Estrogen receptor (ER), progesterone receptor (PR) status

   ER^-PR^-

Reference

Reference

Reference

Reference

   ER⁺PR^-

0.9 (0.5 to 1.5)

1.2 (0.6 to 2.4)

0.9 (0.4 to 1.8)

1.0 (0.5 to 2.1)

   ER^-PR⁺

1.9 (0.9 to 4.0)

1.5 (0.6 to 3.7)

2.6 (1.1 to 6.0)

2.8 (1.2 to 6.7)

   ER⁺PR⁺

0.9 (0.6 to 1.4)

1.1 (0.7 to 1.8)

2.0 (1.2 to 3.3)

2.1 (1.3 to 3.6)